Evaluation of Effects of the Chinese Herbal Medicine
*Jia Wei Liu Jun Zi* Granules on the Treatment of Idiopathic Parkinson’s Disease:
A Randomized, Double-Blind, Placebo-Controlled Pilot Study

KUM Wan Fung

A thesis submitted in partial fulfillment of the requirements
for the degree of
Master of Philosophy

Principal Supervisor: Dr. LI Min

Hong Kong Baptist University

December 2008
ABSTRACT

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease and is anticipated to increase the economic and social burden on communities throughout the world as population ageing. The chronic levodopa treatment of PD is usually complicated by the development of side effects including motor complications. Both the symptoms of PD and adverse effects of conventional therapy can prominently affect patient’s quality of life. Traditional Chinese medicine (TCM) has a long history of application in the treatment of PD. However, Solid scientific evidence is not available despite its widespread use among patients in Asia. The aim of the current study was to investigate the effect of a Chinese herbal medicine, *Jia Wei Liu Jun Zi* (*JWLJZ*) Granules in PD via randomized, double blind, placebo-controlled clinical trial.

Methods: Fifty-five patients with mild-to-advanced idiopathic PD (mean age/standard deviation [SD], 62.5/9.9 years; disease duration 6.1/4.9 years; 36 men [65%]) were recruited from the community. They were randomly allocated to receive either *JWLJZ* Granules 35g or placebo with each dose of their current Western medicine treatment regimen. The primary outcome measure was the 39-item Parkinson’s Disease Questionnaire (PDQ-39). Secondary outcome measures included the Unified Parkinson’s Disease Rating Scale (UPDRS), Short-Form-36 Health Survey (SF-36), Geriatric Depression Scale (GDS), home diaries, and a range of category rating scales.
Results: *JWLJZ* Granules resulted in a significant improvement in the UPDRS IVC when compared with placebo at 12 (-0.45 ± 0.74 vs. -0.04 ± 0.79, p=0.039) and 24 weeks (-0.59 ± 0.80 vs. -0.08 ± 0.81, p=0.034). In addition, patients in *JWLJZ* Granules group also have a significant improvement in PDQ-39 communication scores at 12 (-4.17 ± 19.03 vs. 6.92 ± 13.27, p=0.024) and 24 weeks (-3.79 ± 18.67 vs. 5.92 ± 13.87, p=0.047) when compared to placebo group. There were no significant differences between treatment and control groups for any of the SF-36 variables, GDS score or the mean daily on-off time. No serious adverse effects were found. One case of mild diarrhea was noted in *JWLJZ* Granules group.

Conclusions: The above results showed that *JWLJZ* Granules combined with conventional Western medicine treatment, was well tolerated and showed good efficacy in terms of relieving some non-motor complications including anorexia, nausea, vomiting, insomnia, hypersomnolence and symptomatic orthostasis. In addition, adjunctive use of *JWLJZ* Granules provided additional clinical benefits on communication ability in this group of patients with mild-to-advanced idiopathic PD. The results of this pilot study warrant larger multi-center controlled studies to examine long term efficacy, tolerability and mechanisms of *JWLJZ* Granules in PD function.
# TABLE OF CONTENTS

DECLARATION...........................................................................................................i

ABSTRACT..................................................................................................................ii

ACKNOWLEDGEMENTS............................................................................................iv

TABLE OF CONTENTS...............................................................................................vi

LIST OF FIGURES........................................................................................................x

LIST OF TABLES...........................................................................................................xi

LIST OF ABBREVIATIONS.........................................................................................xiii

PART I LITERATURE REVIEW.....................................................................................1

1.1 Introduction to Parkinson’s Disease.................................................................1

  1.1.1 Epidemiology..............................................................................................2

  1.1.2 Etiology.......................................................................................................6

  1.1.3 Pathogenesis..............................................................................................15

  1.1.4 Clinical Manifestations............................................................................18

1.2 Conventional Treatment of Parkinson’s Disease..............................................25

  1.2.1 Pharmacological Treatments....................................................................26

  1.2.2 Neurosurgical Treatments.....................................................................34

  1.2.3 Complications of Levodopa Treatment.................................................38

1.3 Quality of Life in Patients with Parkinson’s Disease........................................44

  1.3.1 Impact of Young-Onset Parkinson’s Disease.........................................45

  1.3.2 Impact of Motor Complications...............................................................46

  1.3.3 Impact of Depression...............................................................................47

1.4 Parkinson’s Disease in The Context of Traditional Chinese Medicine...........48

  1.4.1 Theory of Traditional Chinese Medicine................................................48

  1.4.2 Pathogenesis of Parkinson’s Disease in Traditional

                   Chinese Medicine............................................................................51

  1.4.3 Treatment of Parkinson’s Disease in Chinese Herbal Medicine.............52
PART II  A RANDOMIZED-CONTROLLED CLINICAL TRIAL of

*JIA WEI LIU JUN ZI GRANULES* ................................................................. 58

1  BACKGROUND ....................................................................................... 58

2  AIM AND OBJECTIVES OF STUDY ...................................................... 61

3  MATERIALS AND METHODS ............................................................... 63

   3.1  Participants ....................................................................................... 63

       3.1.1  Diagnostic Criteria ..................................................................... 63

       3.1.2  Inclusion Criteria ...................................................................... 64

       3.1.3  Exclusion Criteria ..................................................................... 65

       3.1.4  Informed Consent Form ............................................................ 66

   3.2  Settings and Locations ...................................................................... 66

   3.3  Ethics Committee Approval ............................................................ 66

   3.4  Medication and Compliance Monitoring ......................................... 67

   3.5  Intervention ...................................................................................... 67

       3.5.1  Preparation of Chinese Herbal Medicine ..................................... 67

       3.5.2  Quality Control of Chinese Herbal Medicine .............................. 71

       3.5.3  Administration of Chinese Herbal Medicine ............................... 72

   3.6  Outcome Measures ........................................................................... 73

   3.7  Randomization .................................................................................. 77

       3.7.1  Sequence Generation ................................................................. 77

       3.7.2  Allocation Concealment ............................................................... 77

       3.7.3  Implementation .......................................................................... 78

   3.8  Blinding ............................................................................................. 78

   3.9  Statistical Methods ........................................................................... 78

4  RESULTS ................................................................................................. 80

   4.1  Patient Characteristics ..................................................................... 82

   4.2  Treatment Effects within Groups (Time Factor) ............................... 84

       4.2.1  PDQ-39 .................................................................................... 84

       4.2.2  UPDRS ..................................................................................... 86

       4.2.3  SF-36 ......................................................................................... 88
REFERENCES..................................................................................................................122
APPENDIX I. Informed consent..........................................................................................162
APPENDIX IIA. The 39-item Parkinson’s Disease Questionnaire.....................................164
APPENDIX IIB. Unified Parkinson’s Disease Rating Scale.............................................169
APPENDIX IIC. Short Form-36 Health Survey.................................................................171
APPENDIX IID. Geriatric Depression Scale.................................................................175
APPENDIX IIE. Deficiency of Spleen Qi Scale...............................................................177
APPENDIX IIF. Home Diaries..........................................................................................178
APPENDIX IIG. Adverse Effects Induced by Western Medicine......................................180
CURRICULUM VITAE.....................................................................................................181